Extracellular Mutations of Protease-Activated Receptor-1 Result in Differential Activation by Thrombin and Thrombin Receptor Agonist Peptide

2000 ◽  
Vol 58 (6) ◽  
pp. 1178-1187 ◽  
Author(s):  
Brian D. Blackhart ◽  
Lily Ruslim-Litrus ◽  
Chin-Chun Lu ◽  
Veronica L. Alves ◽  
Willy Teng ◽  
...  
Keyword(s):  
Receptor Agonist ◽  
Thrombin Receptor ◽  
Differential Activation ◽  
Agonist Peptide ◽  
Protease Activated Receptor 1

Thrombin Receptor Agonist Peptide Induction of Mitogenesis in CCL39 Cells

1993 ◽  
Vol 190 (3) ◽  
pp. 1001-1008 ◽  
Author(s):  
C.F. Reilly ◽  
T.M. Connolly ◽  
D.M. Feng ◽  
R.F. Nutt ◽  
E.J. Mayer
Keyword(s):  
Receptor Agonist ◽  
Thrombin Receptor ◽  
Agonist Peptide ◽  
Ccl39 Cells

Thrombin receptor agonist peptide immobilized in microspheres stimulates reparative processes in rats with gastric ulcer

2006 ◽  
Vol 142 (1) ◽  
pp. 35-38 ◽  
Author(s):  
A. V. Rusanova ◽  
A. M. Makarova ◽  
S. M. Strukova ◽  
E. A. Markvicheva ◽  
L. R. Gorbachyova ◽  
...  
Keyword(s):  
Gastric Ulcer ◽  
Receptor Agonist ◽  
Thrombin Receptor ◽  
Agonist Peptide

Differential Mobilization of Tyrosine Kinases in Human Platelets Stimulated with Thrombin or Thrombin Receptor Agonist Peptide

1996 ◽  
Vol 225 (3) ◽  
pp. 1084-1089 ◽  
Author(s):  
Kaneo Satoh ◽  
Yukio Ozaki ◽  
Naoki Asazuma ◽  
Yutaka Yatomi ◽  
Qi Ruomei ◽  
...  
Keyword(s):  
Tyrosine Kinases ◽  
Receptor Agonist ◽  
Human Platelets ◽  
Thrombin Receptor ◽  
Agonist Peptide

Minimal sequence requirement of thrombin receptor agonist peptide

1992 ◽  
Vol 184 (2) ◽  
pp. 790-796 ◽  
Author(s):  
Kwan Y. Hui ◽  
Joseph A. Jakubowski ◽  
Virginia L. Wyss ◽  
Eddie L. Angleton
Keyword(s):  
Receptor Agonist ◽  
Thrombin Receptor ◽  
Agonist Peptide ◽  
Minimal Sequence

Antibodies to Protease-Activated Receptor 3 Inhibit Activation of Mouse Platelets by Thrombin

Blood ◽  
1998 ◽  
Vol 91 (11) ◽  
pp. 4152-4157 ◽  
Author(s):  
Hiroaki Ishihara ◽  
Dewan Zeng ◽  
Andrew J. Connolly ◽  
Carmen Tam ◽  
Shaun R. Coughlin
Keyword(s):  
Platelet Activation ◽  
Receptor Agonist ◽  
Thrombin Receptor ◽  
Definitive Evidence ◽  
Mouse Homologue ◽  
Thromboxane Receptor ◽  
Protease Activated Receptor 1

Recent studies of mice deficient in the thrombin receptor, protease-activated receptor 1 (PAR1), provided definitive evidence for the existence of a second thrombin receptor in mouse platelets. We recently identified a new thrombin receptor designated protease-activated receptor 3 (PAR3). The mRNA encoding a mouse homologue of PAR3 was highly expressed in mouse splenic megakaryocytes, making it a good candidate for the missing mouse platelet thrombin receptor. We now report that PAR3 protein is expressed on the surface of mouse platelets and that PAR3 antibodies partially inhibit activation of mouse platelets by thrombin but not U46619, a thromboxane receptor agonist. These observations suggest that PAR3 contributes to mouse platelet activation by thrombin.

Biodegradable microparticles loaded with thrombin receptor agonist peptide for gastric ulcer treatment in rats

2006 ◽  
Vol 16 (4) ◽  
pp. 321-325 ◽  
Author(s):  
E. Markvicheva ◽  
K. Stashevskaya ◽  
S. Strukova ◽  
I. Prudchenko ◽  
A. Rusanova ◽  
...  
Keyword(s):  
Gastric Ulcer ◽  
Receptor Agonist ◽  
Thrombin Receptor ◽  
Agonist Peptide ◽  
Biodegradable Microparticles ◽  
Ulcer Treatment

The Effects of Heparinase 1 and Protamine on Platelet Reactivity 

1997 ◽  
Vol 86 (6) ◽  
pp. 1382-1386 ◽  
Author(s):  
Tameshwar Ammar ◽  
Cherie F. Fisher
Keyword(s):  
Healthy Volunteers ◽  
Receptor Agonist ◽  
Platelet Reactivity ◽  
Institutional Review Board ◽  
Thrombin Receptor ◽  
Agonist Peptide ◽  
Institutional Review ◽  
Heparin Anticoagulation ◽  
Baseline Values ◽  
Stimulation Of

Background Protamine is currently the most widely used drug for the reversal of heparin anticoagulation. Heparinase 1 (heparinase) is being evaluated as a possible alternative to protamine for the reversal of heparin anticoagulation. The authors evaluated the effects of equivalent doses of heparinase and protamine on platelet reactivity by measuring agonist-induced P-selectin expression. Methods After Institutional Review Board (IRB) approval, informed consent was obtained from 12 healthy volunteers and 8 patients undergoing surgery requiring cardiopulmonary bypass (CPB). Twenty-four ml of blood was obtained from each volunteer; 10 ml of blood was obtained from each patient before the CPB, and another 10 ml was obtained after CPB. Heparin was neutralized using heparinase or protamine. Platelet reactivity was assessed by measuring the expression of P-selectin after stimulation of platelets with increasing concentrations of a thrombin receptor agonist peptide (TRAP). Data were analyzed using analysis of variance. P < 0.05 was considered significant. Results For the healthy volunteers, the activated coagulation times (ACTs) of the heparinized samples returned to baseline values with heparinase (12.5 U/ml) or protamine (32.5 microg/ml). For the 8 patients, the ACTs returned to baseline with heparinase (20 U/ml) or protamine (50 microg/ml). The authors found no difference in the expression of P-selectin in samples neutralized with heparinase, but samples neutralized with protamine showed a significant decrease in the expression of P-selectin when compared with heparinized samples. Conclusions At dosages that reverse the anticoagulant effects of heparin, heparinase has minimal effects on platelets, whereas platelet reactivity was markedly inhibited by protamine.

Sign in / Sign up

Export Citation Format

Share Document